$Tonix Pharmaceuticals(TNXP)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Tonix Pharmaceuticals (TNXP) Overview
Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions.
Recent News and Events
Here are some of the recent news and events related to Tonix Pharmaceuticals:
Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article
ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article
Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article
Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article
BIO-Europe® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-Europe® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article
Conclusion
Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions.
Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
How to open a CBA.
How to link your CDP account.
Other FAQs on CBA.
Cash Boost Account Website.